Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.69 |
| ▸ | KDR | P35968 | 9/20 | 0.69 |
| ▸ | RAF1 | P04049 | 7/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | LCK | P06239 | 2/20 | 0.54 |
| ▸ | FYN | P06241 | 2/20 | 0.54 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | RET | P07949 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.54 |
| ▸ | AXL | P30530 | 2/20 | 0.54 |
| ▸ | FRK | P42685 | 2/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13603818 | 0.89 | KDR (0.65) | BRAFKDRRAF1EPHX2MAPK14 | |
| SCHEMBL19478172 | 0.89 | BRAF (0.62) | BRAFKDRRAF1EPHX2 | |
| SCHEMBL15573297 | 0.88 | KDR (0.64) | BRAFKDRRAF1EPHX2MAPK14 | |
| SCHEMBL18681347 | 0.87 | BRAF (0.70) | BRAFKDRRAF1EPHX2MAPK14 | |
| SCHEMBL3578600 | 0.86 | BRAF (0.60) | BRAFKDRRAF1EPHX2MAPK14 | |
| SCHEMBL167964 | 0.86 | KDR (0.68) | BRAFKDRRAF1EPHX2MAPK14 | |
| SCHEMBL16651380 | 0.84 | KDR (0.67) | BRAFKDRRAF1EPHX2MAPK14 | |
| SCHEMBL15545978 | 0.84 | KDR (0.67) | BRAFKDRRAF1EPHX2MAPK14 | |
| SCHEMBL5319531 | 0.84 | KDR (0.67) | BRAFKDRRAF1EPHX2MAPK14 | |
| SCHEMBL177735 | 0.84 | KDR (0.67) | BRAFKDRRAF1EPHX2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653951-B1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| EP-1653951-B1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| US-7691886-B2 | Benzimidazole derivatives as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691886-B2 | Benzimidazole derivatives as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691886-B2 | Benzimidazole derivatives as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| EP-1718614-A1 | PYRIDINAMIDE DERIVATIVE AS KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| EP-1653951-A1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005085202-A1 | PYRIDINAMIDE DERIVATIVE AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005004864-A1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | BRAF, RAF1, VEGFA | BRAF 1/4885KDR 4/4885RAF1 2/4885 |
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | TIE1, KDR, FLT1 | BRAF 49/4885KDR 2/4885RAF1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.